Recursion Pharmaceuticals, Inc. (RXRX) SEC Filings & Earnings Calls

Dilution from equity offering

“61.54M shares at $3.25/share; ~20% dilution”

Elimination of termination for convenience reduces flexibility.

“eliminate the Company’s right to terminate the Agreement for convenience” · word for word

Revenue decline and continued operating losses raise cash burn concerns.

“Total revenue decreased from $19.2M to $7.7M year-over-year; net loss of $131M in Q2 2026.”

Dependence on partnership milestones for non-dilutive funding; any delay could pressure cash runway.

“Partnership milestones from Roche/Genentech and Sanofi are key revenue sources; guidance cut suggests cost control.”

Cash runway uncertainty

“The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates.” · word for word

Revenue concentration on partnerships

“Operating revenue is generated through research and development agreements derived from strategic alliances.” · word for word

Material weakness in internal controls

“Our disclosure controls and procedures were ineffective due to the material weaknesses in internal control over financial reporting disclosed in Part II, Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2025.” · word for word

No approved products; reliance on partnerships and equity financing

“We do not have any products approved for commercial sale and have not generated any revenues from product sales.” · word for word

Accumulated deficit of $2.2 billion

“As of March 31, 2026, our accumulated deficit was $2.2 billion.” · word for word

Need for additional financing

“We anticipate that we will need to raise additional financing in the future to fund our operations, including the potential commercialization of any approved product candidates.” · word for word

Founder departure from Board could signal strategic shift, but remains as advisor

“Chris Gibson will not stand for re-election to the Board”

Supply Chain Disruption

“certain of our specialized equipment, as well as the API used in our drug candidates, are obtained from single-source suppliers” · word for word

Regulatory Compliance Cost

“We are subject to numerous environmental, health and safety, and other laws and regulations” · word for word

Clinical Development Failure

“Our business is dependent on the successful development of our current and future product candidates”

No revenue, net loss, cash burn typical for clinical-stage biotech

“No revenue or net income figures provided; company is pre-revenue”

Clinical trial risk: pipeline failure could impair value

“Dependence on clinical trial outcomes; no approved products”

Forward-looking statements; no specific risk signals in excerpt

“Boilerplate safe harbor language.”

Clinical trial risk; early-stage data may not support regulatory approval or commercial success.

“Phase 1b/2 trial; no specific results disclosed in filing; typical biotech development risk.”

Potential dilution from share issuance for license fees; no cash raised

“7,088,742 shares...issued to Tempus AI, Inc. in payment for annual license fees”

No approved products; ongoing losses

“We do not have any products approved for commercial sale and have not generated any revenues from product sales.” · word for word

Dependence on future financing

“We anticipate that we will need to raise additional financing in the future to fund our operations.” · word for word

Revenue volatility from milestone timing

“The timing of revenue recognition is not directly correlated to the timing of cash receipts.” · word for word

Leadership transition risk; new CEO may shift strategy.

“CEO change announced; no financial impact quantified.”